RxDoctor Payments Data

Mark Shields, MD

Internal Medicine · Laguna Hills, CANPI 1366411555

Payments from drug & device makers

$1,274in general payments, 2019–2025

Across 65 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$311
  • Olympus America Inc.$129
  • Boston Scientific$90
  • Sanofi Pasteur Inc.$71
  • Astellas Pharma US Inc$54
  • Radius Health, Inc.$54
  • plus $565 from 21 others

What the payments were for

  • Food & beverage$1,23397%
  • Gifts$413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,274 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$105,577
Medicare patients
248
Services billed
1,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$110,098
XareltoRivaroxaban59$60,495
JanuviaSitagliptin Phosphate26$26,293
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen174$5,601
Atorvastatin Calcium453$4,315
OxycontinOxycodone Hcl14$3,906
Rosuvastatin Calcium205$3,887
SynthroidLevothyroxine Sodium66$3,547
Pantoprazole Sodium217$3,275
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,120
Levothyroxine Sodium242$2,786
Losartan Potassium256$2,524
Omeprazole118$2,347
Tamsulosin Hcl141$2,090
Gabapentin112$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$110,098107 claims
Johnson & JohnsonXarelto$311$60,49559 claims
MerckJanuvia$49$26,29326 claims
AbbVieSynthroid$32$3,54766 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →